Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength

HLS Therapeutics

12/03/2026 10:45

Overview

Canada pharmaceutical firm's fiscal Q4 revenue declined 2% yr/yr, slightly beating analyst expectations

Adjusted EBITDA for fiscal 2025 grew 18%, driven by cost optimization and operational discipline

Company reduced long-term debt by 26% and annual interest expense by 43% in fiscal 2025

Outlook

HLS Therapeutics targets 2026 revenue of $56-60 mln USD

Company expects 2026 Adjusted EBITDA of $18.5-21 mln USD, relatively flat due to NILEMDO launch costs

Company says exchange rate volatility could impact future results

Result Drivers

VASCEPA GROWTH - Vascepa unit volumes in Canada grew in 2025, supported by sales force changes and expanded provincial access

CLOZARIL DECLINE - Canadian Clozaril sales fell 4% in 2025 due to regional competitive dynamics; U.S. Clozaril sales declined 1.6%, a slower rate than prior years, attributed to the specialty pharmacy program

COST OPTIMIZATION - Operating expenses excluding cost of sales fell 17% in 2025, reflecting discontinuation of co-promotional activities and ongoing cost optimization

Company press release: ID:nCNWvynzka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$15.20 mln
$15 mln (3 Analysts)
Q4 Net Income
-$1.34 mln
Q4 Pretax Profit
-$1.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for HLS Therapeutics Inc is C$8.00, about 87.4% above its March 11 closing price of C$4.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)